TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.

David Bernard Miklos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.